The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Safety Evaluation of Lipid Nanoparticle–Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey
Abstract
The pharmacology, pharmacokinetics, and safety of modified mRNA formulated in lipid nanoparticles (LNPs) were evaluated after repeat intravenous infusion to rats and monkeys. In both species, modified mRNA encoding the protein for human erythropoietin (hEPO) had predictable and consistent pharmacologic and toxicologic effects. Pharmacokinetic analysis conducted following the first dose showed that measured hEPO levels were maximal at 6 hours after the end of intravenous infusion and in excess of 100-fold the anticipated efficacious exposure (17.6 ng/ml) at the highest dose tested. 24 hEPO was pharmacologically active in both the rat and the monkey, as indicated by a significant increase in red blood cell mass parameters. The primary safety-related findings were caused by the exaggerated pharmacology of hEPO and included increased hematopoiesis in the liver, spleen, and bone marrow (rats) and minimal hemorrhage in the heart (monkeys). Additional primary safety-related findings in the rat included mildly increased white blood cell counts, changes in the coagulation parameters at all doses, as well as liver injury and release of interferon γ–inducible protein 10 in high-dose groups only. In the monkey, as seen with the parenteral administration of cationic LNPs, splenic necrosis and lymphocyte depletion were observed, accompanied with mild and reversible complement activation. These findings defined a well-tolerated dose level above the anticipated efficacious dose. Overall, these combined studies indicate that LNP-formulated modified mRNA can be administered by intravenous infusion in 2 toxicologically relevant test species and generate supratherapeutic levels of protein (hEPO) in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In vivo application of lipid nanoparticles has been reported to induce liver and lung injuries in rodents170,173, which may be attributed to the cytotoxicity of the materials and the induction of”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [173]
In the citing paper
“Although the immunogenicity of these lipids has not yet been fully understood, complement system and Toll-like receptors may participate in innate immune activation170,173–175.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [173]
In the citing paper
“Cationic and ionizable lipids have also been reported to stimulate the secretion of pro-inflammatory cytokines and reactive oxygen species170–173.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [173]
Citations
Cites
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · cited 1×
“However, the application of lipid-based nanoparticle delivery systems, initially developed for the in vivo delivery of siRNA, has enabled systemic administration of modified mRNA.(22)”
BackgroundGilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357 · cited 1×
“The mRNA-loaded LNPs were generated via stepwise ethanol dilution, with an approach adapted from previously demonstrated methods.(13,30) The LNP formulation was prepared by dissolving the lipids (6Z,9Z,28Z,31Z)-heptatriaconta6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (MC3), 2 Veterinary Pathology XX(X)”
MethodShatkin, A. J. (1976) · Cell · doi:10.1016/0092-8674(76)90128-8 · Cited by 1,180
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice
Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733
Andries, O., Mc Cafferty, S., De Smedt, S. C., Weiss, R., Sanders, N. N., & Kitada, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.051 · Cited by 701
Nonviral delivery of self-amplifying RNA vaccines
Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 675 · cited 1×
“Adequate delivery of mRNA with lipid nanoparticles (LNPs) has been demonstrated for mRNA-based vaccines, where intramuscular injection of low doses of mRNA formulated in either LNPs or nanoemulsion induced immune protection from influenza and respiratory syncytial virus in mice, as well as cytomegalovirus and respirat…”
BackgroundZangi, L., Lui, K. O., von Gise, A., Ma, Q., Ebina, W., Ptaszek, L. M., Später, D., Xu, H., Tabebordbar, M., Gorbatov, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2682 · Cited by 646
Thess, A., Grund, S., Mui, B. L., Hope, M. J., Baumhof, P., Fotin-Mleczek, M., & Schlake, T. (2015) · Molecular Therapy · doi:10.1038/mt.2015.103 · Cited by 513 · cited 7×
“Consistent with this, neutrophil, monocyte, and atypical lymphocyte counts were elevated across all groups dosed with hEPO-mRNA in LNPs. Interestingly, administration of hEPO-mRNA in LNPs once weekly or empty LNPs did not elicit the same increase in white blood cells (Fig.”
MethodInfluentialNucleic acid sensing at the interface between innate and adaptive immunity in vaccination
Desmet, C. J., & Ishii, K. J. (2012) · Nature reviews. Immunology · doi:10.1038/nri3247 · Cited by 404
The RNA Modification Database: 1999 update
Rozenski, J., Crain, P. F., & McCloskey, J. A. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.196 · Cited by 390
A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA
Jeffs, L. B., Palmer, L. R., Ambegia, E. G., Giesbrecht, C., Ewanick, S., & MacLachlan, I. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-1873-z · Cited by 307
Karikó, K., Muramatsu, H., Keller, J. M., & Weissman, D. (2012) · Molecular Therapy · doi:10.1038/mt.2012.7 · Cited by 282
Lipid-Based Nanocarriers for RNA Delivery
Xue, H. Y., Guo, P., Wen, W., & Wong, H. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150531164540 · Cited by 202
Wang, Y.-H., Su, H.-H., Yang, Y., Hu, Y.-X., Zhang, L., Blancafort, P., & Huang, L. (2013) · Molecular Therapy · doi:10.1038/mt.2012.250 · Cited by 189
Biomaterials for mRNA delivery
Islam, M. A., Reesor, E. K. G., Xu, Y., Zope, H. R., Zetter, B. R., & Shi, J. (2015) · Biomaterials Science · doi:10.1039/c5bm00198f · Cited by 176
Safety profile of RNAi nanomedicines
Barros, S. A., & Gollob, J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.06.007 · Cited by 125
Delivery Strategies for siRNA-mediated Gene Silencing
Gilmore, I. R., Fox, S. P., Hollins, A. J., et al. (2006) · Current Drug Delivery · doi:10.2174/156720106776359159 · Cited by 99
Branched DNA Technology in Molecular Diagnostics
Tsongalis, G. J. (2006) · American Journal of Clinical Pathology · doi:10.1309/90bu6kdxanfln4rj · Cited by 89
Martins, R., Queiroz, J. A., & de Sousa, F. P. (2014) · Journal of Chromatography A · doi:10.1016/j.chroma.2014.05.075 · Cited by 68
Christensen, J. K., Litherland, K., Faller, T., van de Kerkhof, E. G., Natt, F., Hunziker, J., Boos, J. A., Beuvink, I., Bowman, K., Baryza, J. L., et al. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.055434 · Cited by 60
Antibody-mediated side effects of recombinant proteins
Frost, H. (2005) · Toxicology · doi:10.1016/j.tox.2004.12.028 · Cited by 44
Sörgel, F., Thyroff‐Friesinger, U., Vetter, A., et al. (2009) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-9-10 · Cited by 35
Andrews, D. A., Boren, B. M., Turk, J. R., Boyce, R. W., He, Y. D., Hamadeh, H. K., Mytych, D. T., Barger, T. E., Salimi-Moosavi, H., Sloey, B., et al. (2013) · Toxicologic Pathology · doi:10.1177/0192623313486319 · Cited by 6
Research works printed but not linked: 1
- Casadevall N, 2003, Nephrol Dial Transplant, 18, viii37
Cited by
Sorted by citations
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
“Inspired by the success of LNPs, various groups showed that MC3 can also be used to safely transfect mRNA in order to express therapeutic proteins.(32,33) Researchers at Intellia Therapeutics have reported an ionizable lipid named LP-01 (Figure 2) as part of”
Sabnis, S., Kumarasinghe, E. S., Salerno, T., Mihai, C., Ketova, T., Senn, J. J., Lynn, A., Bulychev, A., McFadyen, I., Chan, J., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.010 · Cited by 820
Self-citationCRISPR/Cas9 therapeutics: progress and prospects
Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P., & Yu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01309-7 · Cited by 824
“A gold standard MC-3 LNP configured with cholesterol, DSPC and DMG-PEG was used as a control to screen for the most efficient 306-O12B LNP consisting of a leading tail-branched bioreducible lipidoid (306-O12B) and an optimized mixture of excipient lipid molecules.(197) The gene-editing efficiency of this LNP reached 3…”
Method
Metadata
- Authors
- Sedic, M., Senn, J. J., Lynn, A., Laska, M., Smith, M., Platz, S. J., Bolen, J., Hoge, S., Bulychev, A., Jacquinet, E., Bartlett, V., & Smith, P. F.
- Affiliations
- Moderna Therapeutics (United States) (US)
- AstraZeneca, Melbourn, Royston, UK
- PureTech (United States) (US)
- Akcea Therapeutics, Cambridge, MA
- Alnylam Pharmaceuticals (United States) (US)
- Corresponding author
- Senn, Joseph J.
- Venue
- Veterinary Pathology
- Publisher
- SAGE Publications
- Published
- 2017-11-30
- Volume
- 55
- Issue
- 2
- Pages
- 341-354
- ISSN
- 0300-9858 (ISSN-L)
- 1544-2217
- OpenAlex
- W2774359469
- Semantic Scholar
- ff6e62a333b9a5177911689bb2e6b1d42baa1047
- Cited by
- 195
- References
- 29
- Citations by year
- 2026: 19 · 2025: 22 · 2024: 29 · 2023: 36 · 2022: 36 · 2021: 23 · 2020: 13 · 2019: 10 · 2018: 6
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Veterinary Pathology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Moderna
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- modified mRNA, human erythropoietin, intravenous infusion, hematopoiesis, splenic necrosis, lymphocyte depletion, complement activation, CXCL10, liver injury, coagulation parameters, nonclinical safety evaluation
- MeSH terms
- Animals, Blood Coagulation, Erythropoietin, Female, Hematopoiesis, Infusions, Intravenous, Leukocyte Count, Lipids, Macaca fascicularis, Male, RNA, Messenger, Rats, Sprague-Dawley, Rats, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
